Member Contact: Paul MacLeman
Position: Executive Chairman
Industry: Biotech & Pharmaceuticals
AdAlta Limited is an Australian-based drug development company headquartered in Melbourne. AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. The company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics with the affinity of monoclonal antibodies and the beneficial stability features of small molecules. AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.